<DOC>
	<DOC>NCT00696657</DOC>
	<brief_summary>This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.</brief_summary>
	<brief_title>A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Men and womennotofchildbearing potential diagnosed with type 2 diabetes for at least three months Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months HbA1c: 7.010.0 % (both inclusive) Body weight between 60 kg and 110 kg Treatment with insulin, GLP1 receptor agonists (including liraglutide), dipeptidyl peptidase4 inhibitors, sulphonylurea, thiazolidinediones, AlphaGIs, or any investigational drug, within the last three months Impaired liver or kidney function Proliferative retinopathy or maculopathy requiring acute treatment Clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension Recurrent major hypoglycaemia or hypoglycaemic unawareness Present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>